Download Files:
Products Details
Product Description
– N3-PEG8-Phe-Lys-PABC-Gefitinib is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC. N3-PEG8-Phe-Lys-PABC-Gefitinib is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
Web ID
– HY-131088
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C60H81ClFN11O15
Molecular Weight
– 1250.80
SMILES
– ClC1=C(C=CC(NC2=NC=NC3=C2C=C(C(OC)=C3)OCCCNC(OCC4=CC=C(NC([C@H](CCCCN)NC([C@@H](NC(CCOCCOCCOCCOCCOCCOCCOCCOCCN=[N+]=[N-])=O)CC5=CC=CC=C5)=O)=O)C=C4)=O)=C1)F
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– Drug-Linker Conjugates for ADC
Isoform
– Traditional Cytotoxic Agents
Pathway
– Antibody-drug Conjugate/ADC Related
Product type
– ADC Related
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
